Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy

[21] Hanin A(1983)Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases J Neurol Sci 60 39-482

[22] Lambrecq V(2004)Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson’s disease Mov Disord 19 461-547

[23] Denis JA(2005)S100B and NSE serum levels in patients with Parkinson’s disease Parkinsonism Relat Disord 11 156-374

[24] Imbert-Bismut F(2020)Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson’s disease dementia Eur Arch Psychiatry Clin Neurosci 270 480-188

[25] Rucheton B(2020)Increased cerebrospinal fluid S100B and NSE reflect neuronal and glial damage in Parkinson’s disease Front Aging Neurosci 12 539-629

[26] Lamari F(2007)CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy Parkinsonism Relat Disord 13 369-448

[27] Kim HJ(2016)A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers Neurology. 87 479-100

[28] Tsao JW(2005)Cerebrospinal fluid and serum neuron-specific enolase concentrations in a normal population Eur J Neurol 12 184-undefined

[29] Stanfill AG(2020)The neuropathological diagnosis of Alzheimer’s disease-the challenges of pathological mimics and concomitant pathology Brain Sci 10 614-undefined

[30] Wan X(1999)Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia J Neurol Neurosurg Psychiatry 66 436-undefined

[21] Hanin A(1983)Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases J Neurol Sci 60 39-482

[22] Lambrecq V(2004)Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson’s disease Mov Disord 19 461-547

[23] Denis JA(2005)S100B and NSE serum levels in patients with Parkinson’s disease Parkinsonism Relat Disord 11 156-374

[24] Imbert-Bismut F(2020)Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson’s disease dementia Eur Arch Psychiatry Clin Neurosci 270 480-188

[25] Rucheton B(2020)Increased cerebrospinal fluid S100B and NSE reflect neuronal and glial damage in Parkinson’s disease Front Aging Neurosci 12 539-629

[26] Lamari F(2007)CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy Parkinsonism Relat Disord 13 369-448

[27] Kim HJ(2016)A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers Neurology. 87 479-100

[28] Tsao JW(2005)Cerebrospinal fluid and serum neuron-specific enolase concentrations in a normal population Eur J Neurol 12 184-undefined

[29] Stanfill AG(2020)The neuropathological diagnosis of Alzheimer’s disease-the challenges of pathological mimics and concomitant pathology Brain Sci 10 614-undefined

[30] Wan X(1999)Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia J Neurol Neurosurg Psychiatry 66 436-undefined